Development for DC Vaccine using Th1/Th17 axis by IL-23

• Project/Area Number: 19790913
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Single-year Grants
• Research Field: General surgery
• Research Institution: The University of Tokyo
• Principal Investigator: SATO Marimo The University of Tokyo, 医科学研究所, 助教 (50401253)
• Project Period (FY): 2007 – 2008
• Project Status: Completed (Fiscal Year 2008)
• Budget Amount: ¥3,780,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥480,000); Fiscal Year 2008: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000); Fiscal Year 2007: ¥1,700,000 (Direct Cost: ¥1,700,000)
• Keywords: IL-23 / 樹状細胞 / 癌ワクチン / Th1 / Th17 / 免疫学 / サイトカイン / 癌治療 / 遺伝子治療

Research Abstract

本応募研究課題では、成熟化樹状細胞(dendritic cell: DC)からの産生されるIL-23の抗腫瘍免疫応答の誘導における機能的役割、とりわけ、IL-23で活性化されるTh1およびTh17の抗腫瘍免疫応答における役割を明らかにすることに焦点を絞り、IL-23を高産生するOK-432およびPGE2成熟化DCと、IL-23遺伝子導入DCを作製し、この2つのIL-23産生DCを用いて研究を進めた。そして、その腫瘍免疫における有用性を明らかにし、最終的にはIL-23産生DCを用いた癌特異的DCワクチンを臨床試験へトランスレーショナルを目的としたいと考えている。

Research Products

• [Journal Article] Combined mobilization and stimulation of tumor-infiltrating dendritic cells and natural killer cells with Flt3 ligand and IL-18 in vivo induces systemic anti-tumor immunity (2008)
  • Author(s): Testuya Saito, Takuya Takayama, Tadashi Osaki, Shigenori Nagai, Toshihiro Suzuki, Marimo Sato, Hiroyuki Kuwano and Hideaki Tahara
  • Journal Title: Cancer Sci 99 Pages: 36-2028
  • NAID: 10024012190
• [Journal Article] Combined mobilization and stimulation of tumor-infiltrating dendritic cells and natural killer cells with Flt3 ligand and IL-18 in vivo induces systemic anti-tumor immunity (2008)
  • Author(s): Testuya Saito, Takuya Takayama, Tadashi Osaki, Shigenori Nagai, Toshihiro Suzuki, Marimo Sato, Hiroyuki Kuwano and Hideaki Tahara
  • Journal Title: Cancer Science 99 Pages: 2028-2036
  • NAID: 10024012190
  • Peer Reviewed
• [Journal Article] Systemic Administration of IL-23 Induces Potent Anti-tumor Immunity Primarily Mediated through Th1-type Response in Association with the Endogenously Expressed IL-12 (2007)
  • Author(s): Teruo Kaiga, Marimo Sato,Hide Kaneda, Yoichiro Iwakura, Tadatoshi Takayamam, and Hideaki Tahara
  • Journal Title: J Immunol 178 Pages: 7571-7580
• [Journal Article] Potent anti-tumor effects of combination therapy using Interleukin-23 and a-galactosylceramide (2007)
  • Author(s): Hide Kaneda, Marimo Sato, Teruo Kaiga, Yoko Nango, Takeshi Kusafuka, and Hideaki Tahara
  • Journal Title: J. Nihon Univ. Med. Ass 66 Pages: 60-69
• [Journal Article] Systemic Administration of IL-23 Induces Potent Anti-tumor Immunity Primarily Mediated through Th1-type Response in Association with the Endogenously Expressed IL-12 (2007)
  • Author(s): Teruo Kaiga, Marimo Sato, Hide Kaneda, Yoichiro Iwakura, Tadatoshi Takayamam, and Hideaki Tahara
  • Journal Title: J Immunol 178 Pages: 7571-7580
  • Peer Reviewed
• [Presentation] Systemic administration of IL-23 induces potent anti-tumor immunity primarily mediated through Th1-type response in association with the endogenously expressed IL-12 (2008)
  • Author(s): Marimo Sato, Hide Kaneda, Teruo Kaiga and Hideaki Tahara
  • Organizer: 99^<th> Annual Meeting of AACR
  • Place of Presentation: San Diego
• [Presentation] Systemic administration of IL-23 induces potent anti-tumor immunity primarily mediated through Th1-type response (2008)
  • Author(s): Marimo Sato, Hide Kaneda, Kimiyasu Yoneyama, Hideaki Tahara
  • Organizer: An AACR International Conference
  • Place of Presentation: Jordan.
• [Presentation] Systemic administration of IL-23 induces potent anti-tumor immunity primarily mediated through Thl-type response in association with the endogenously expressed IL-12 (2008)
  • Author(s): Marimo Sato, Hide Kaneda, Teruo Kaiga and Hideaki Tahaia
  • Organizer: 99^<th> Annual Meeting of AACR
  • Place of Presentation: San Diego, USA
• [Presentation] Systemic Administration of IL-23 Induces Potent Anti-tumor Immunity Primarily Mediated through Th1-type Response in association with the endogenous expressed IIL-12 (2008)
  • Author(s): Marimo SATO, Hide KANEDA, Teruo KAIGA and Hideaki TAHARA
  • Organizer: AACR International Conference: Advanced in Cancer research
  • Place of Presentation: Dead Sea, Jordan
• [Presentation] Potent anti-tumor immunity and both Th1 and Th17 promotion associated with IL-23 administration (2007)
  • Author(s): Hideaki Tahara, Hide Kaneda, Teruo Kaiga and Marimo Sato
  • Organizer: 第37回日本免疫学会学術総会
  • Place of Presentation: 東京
• [Presentation] Th1 and Th17 in IL-23 induced anti-tumor immune responses (2007)
  • Author(s): Marimo Sato, Hide Kaneda, Kunimitsu Komatsu, Teruo Kaiga and Hideaki Tahara
  • Organizer: 第37回日本免疫学会学術総会
  • Place of Presentation: 東京
• [Presentation] IL-23 の全身投与によるTh1 およびTh17誘導を介した抗腫瘍効果 (2007)
  • Author(s): 金田英秀、佐藤まりも、海賀照夫、田原秀晃
  • Organizer: 第11回基盤的癌免疫研究会総会
  • Place of Presentation: 東京
• [Presentation] Potent anti-tumor effects of combination therapy using Interleukin-23 and α-galactosylceramide (2007)
  • Author(s): Hide Kaneda, Marimo Sato, Hideaki Tahara
  • Organizer: 98^<th> Annual Meeting of AACR
  • Place of Presentation: Los Angles
• [Presentation] Th1 and Th17 in IL-23 induced anti-tumor immune responses (2007)
  • Author(s): 佐藤まりも、金田英秀、小松邦光、海賀照夫、田原秀晃
  • Organizer: 第37回 日本免疫学会学術総会 ワークショップ
  • Place of Presentation: 東京
• [Presentation] T Systemic administration of IL-23 induces potent anti-tumor immunity and both Th1-and Th17-type responses (2007)
  • Author(s): 佐藤まりも、金田英秀、海賀照夫、田原秀晃
  • Organizer: 第66回 日本癌学会学術総会 シンポジウム
  • Place of Presentation: 横浜
• [Presentation] Potent anti-tumor effects of combination therapy using Interleukin-23 and α-galactosylceramide (2007)
  • Author(s): Hide Kaneda, Marimo Sato, Hideaki Tahara
  • Organizer: 98th Annual meeting of AACR
  • Place of Presentation: Los Angels, USA
• [Book] IL-23の全身投与による抗腫瘍効果 (2008)
  • Author(s): 佐藤まりも、田原秀晃
  • Total Pages: 4
  • Publisher: 先端医学社
• [Book] がんワクチンの開発 (2007)
  • Author(s): 佐藤まりも、田原秀晃
  • Total Pages: 4
  • Publisher: 月刊・治療学